Wendy A Hudson

Wendy A Hudson is a Researcher at the University of Minnesota's Office of Academic Clinical Affairs, focusing on cancer genetics and molecular mechanisms of tumor progression. Her work spans leukemia, osteosarcoma, and hepatocellular carcinoma, utilizing mouse models and genomic techniques.

• Key affiliations: Office of Academic Clinical Affairs (University of Minnesota)
• Research areas: Cancer genetics, MLL-fusion leukemia, ZNF217 signaling, steatosis-associated hepatic tumors

Her research employs CRISPR technology, Sleeping Beauty mutagenesis, and pharmacological inhibitors like PLX3397 to study oncogenic pathways such as ERK and PI3K-AKT. Collaborations include D.A. Largaespada, B.S. Moriarity, and J.H. Kersey.

Recent publications (2020) examine ZNF217's role in osteosarcoma and CSF1R inhibition effects, while 2017 work explores steatosis-associated liver tumors using transposon systems. Earlier studies (2009-2011) investigate MEIS1's function in leukemia and developmental differences in leukemogenesis.

Scientific impact: 7 research outputs with 87-40 Scopus citations, including 1 patent reference. Mentions in 13-19 Mendeley readers and social media engagement.